Advertisement

Related Videos

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Advertisement

Advertisement




Sep
01
Today In Oncology
Radiation to the Thymus in NSCLC Treatment May Increase Risk of Metastasis
Osimertinib Plus Chemotherapy Significantly Extends Progression-Free Survival in EGFR/TP53-Mutated NSCLC
Two Studies Build Evidence Supporting the Use of ctDNA as an Early Endpoint
The 2026 ASCO Annual Meeting Geriatric Oncology Update: The Next Challenge Is Implementation
Researchers Identify Donor NK Cell Subset That Impairs CAR NK Cell Therapy and Demonstrate a Manufacturing Solution
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo